News | Breast Imaging | June 28, 2017

Laser Imaging "Bowl" to Give Instant Test for Breast Cancer

European scientists developing photoacoustic imaging system to increase patient comfort and shorten the diagnostic process

Laser Imaging "Bowl" to Give Instant Test for Breast Cancer

June 28, 2017 — In a bid to make the world's first while-you-wait test for breast cancer, European scientists are developing a comfortable hemispherical bowl lined with laser sources and ultrasound detectors with the potential to reduce the stages in spotting the disease into a single appointment.

Current breast cancer diagnosis can be distressing and painful over a number of weeks. Multiple stages can involve visiting a general practitioner, being sent to a specialist for an X-ray mammogram, having an ultrasound, before undergoing a needle, a punch or a vacuum assisted biopsy, as well as placing one breast at a time between two metal plates in a painful clamp.

However, a new imaging system being developed by scientists at the University of Twente in the Netherlands intends to remove the discomfort and uncertainty involved in a diagnosis.

The device employs both light and sound together in a technique called photoacoustics, combining lasers and photonics with ultrasound detection.

The size of a hospital bed, a patient lies face down placing their breast snugly into the ‘reader’, a hemispherical ‘bowl’ lined with up to a hundred optical fibers and several ultrasound detectors.

Multiple images of a suspect breast and tumor are then acquired from dozens of different angles before assembling the multiple shots into a single 3-D image. 

The ‘PAMMOTH’ (Photoacoustic Ultrasound Mammoscopy for evaluating screening-detected abnormalities in the breast), hopes to lead the researchers into photoacoustic, real-time 3-D imaging of suspicious lesions.

Project coordinator Srirang Manohar explained, “We are creating an imaging device that we hope will reduce all of the stages involved in spotting breast cancer into one convenient appointment in order to reduce time, uncertainty and the number of unnecessary biopsies. We intend to make breast cancer diagnosis a one-stop-shop, while you wait.”

It works by sending short pulses of light into the breast towards the suspected lesion. Some of the delivered energy will be absorbed in the tissue and converted into heat, leading to transient thermoelastic expansion, or a mechanical ‘push’ signal from the suspected tumor.

Ultrasound detectors on the surface of the breast, from the hemispherical reader bowl where the breast is placed, can then detect and measure these push signals before analyzing them on-site. Here the imager can look into the hemoglobin (the oxygen-carrying protein in the blood) activity within the suspected tumor.

Since tumors consume oxygen at high rates to survive, lower oxygenation levels around a suspect lesion could tell a physician that a suspect lump is more likely to be a malignant growth than not.

The imager employs a multi-wavelength illumination in the near-infrared wavelength region to extract information about blood oxygenation, using PAMMOTH’s own image reconstruction methods.

As part of the PAMMOTH team, researchers at University College London (UCL) are working on the mathematics, the image reconstruction and the analysis of the signals to determine how aggressive a tumor could be.

By gathering key information about the hemoglobin and oxygenation levels to and from the suspected tumor, the user could diagnose how likely it would be for the tumor to spread or whether it was simply benign.

“An aggressive tumor has a high metabolism and consumes oxygen more rapidly than normal tissue or a benign lesion. Our instrument and the mathematical approaches we are developing could allow us to check the oxygen saturation rate accurately,” said Manohar. “If a patient’s oxygen saturation rate was found to be considerably lower than surrounding tissue then we could pinpoint where an aggressive tumor could be, and radiologists could understand how the tumor is likely to behave.”

Current techniques to diagnose breast cancer such as X-ray mammography, ultrasound or magnetic resonance imaging (MRI) scans can sometimes fail to spot a tumor from healthy tissue or a benign abnormality, resulting in tumors that are missed and unnecessary biopsies being carried out.

Unnecessary biopsies and risks of false positives in breast cancer diagnosis are hotly contested topics among medical experts. As well as the untold stress and discomfort experienced by women all over the world by unnecessary treatments, inefficient diagnoses have an extremely worrying cost implication.

Every year in the United States alone, $4 billion is spent on false-positive mammograms and breast cancer over diagnosis among women ages 40-59, according to research published in Health Affairs. A similar picture is played out across Europe with millions of Euros being spent on unnecessary mammograms.

“A prime focus of the PAMMOTH project is to develop an imager and data analysis to be able to intervene at a very early stage. We need to be able to say whether a suspect lesion is good or bad. This technique would have a substantial impact upon the money spent on unnecessary biopsies, as well as to remove the trauma involved in a diagnosis for women around the world,” said Manohar.

The PAMMOTH team hopes to have a prototype ready for 2020 ready for completion in 2021.

Coordinated in the Netherlands at the University of Twente, the PAMMOTH project received a grant of €4,352,007.50 from Horizon 2020 via the Photonics Public Private Partnership.

For more information: www.photonics21.org

Related Content

Eizo RadiForce RX560 Monitor Receives FDA 510(k) for Tomosynthesis and Digital Mammography
Technology | November 20, 2017
Eizo Corp. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for breast tomosynthesis...
Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Technology | Women's Health | November 13, 2017
November 13, 2017 — Biop Medical announced it will present its point-of-care...
Kansas City Radiology Center Employs iCAD PowerLook Tomo Detection for DBT
News | Computer-Aided Detection Software | November 10, 2017
November 10, 2017 — Imaging for Women, a leading radiology center in Kansas City, Mo., announced it is now using iCAD
Kubtec Brings Image Analytics Capabilities to Tomosynthesis Specimen Imaging Systems
News | Mammography | November 10, 2017
Kubtec announced it will be showcasing new image analytics capabilities on its advanced tomosynthesis specimen imaging...
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Imaging | November 10, 2017
November 10, 2017 — To address the specific needs of...
Fujifilm Highlights Women's Health and Pediatrics at RSNA 2017
News | Information Technology | November 08, 2017
November 8, 2017 — Fujifilm Healthcare will showcase a variety of imaging and information technology solutions at the
CureMetrix Expands Medical Advisory Board
News | Computer-Aided Detection Software | November 08, 2017
November 8, 2017 — CureMetrix, a company developing...
ICPME Makes EQUIP Mammography Inspection CME/CE Webinar Available Online
News | Mammography | November 08, 2017
November 8, 2017 — In conjunction with Brea...
Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust
News | Radiation Therapy | November 06, 2017
November 6, 2017 — Nearly one-third of women with...
Study shows tissue marker reduces radiation target volumes, produces many other advantages

These CT images show placement of a 3-D fixed array implanted fiducial (3-D marker) at the time of oncoplastic tumor resection. The original LCTV (LCTVo) was retrospectively re-contoured by the radiation oncologist (LCTVro) and breast surgeon (LCTVbs). Thereafter, both re-contours were combined to create the collaborative LCTV (LCTVc), which required agreement of both the radiation oncologist and breast surgeon. Volume differences between the original LCTV (LCTVo) and the collaborative LCTVc were then evaluated, and demonstrated a mean and median reduction in LCTV.

Feature | Tumor Tracking Systems | November 06, 2017 | By William Hall, M.D.
Radiation planning for breast cancer relies on accurate delineation of the post-lumpectomy target volume as identified...
Overlay Init